Generic Firms Break Camp; FDA Says “First-To-File” Covers Same-Day ANDAs

FDA's guidance defining "first-to-file" status for generic drug companies launching patent challenges offers some relief for ANDA applicants jockeying for position at the agency - and may offer a further impetus for changes to the current 180-day exclusivity system